300 Shire Way
Tel: 617 349 0200
About Shire Pharmaceuticals
There’s a simple purpose that sits at the heart of our business: to enable people with life-altering conditions to lead better lives. This means we focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients.
Our growth strategy is to focus on developing and marketing innovative specialty medicines for symptomatic conditions to meet significant unmet patient needs. Our two strategic priorities are to drive optimum performance of our existing products, enabling access to these medicines for patients today; and building our pipeline through research and development (R&D) and business development (BD), delivering access in the future for patients We are always looking for talented people to join the Shire team.
To learn more about Shire, visit www.shire.com.
For more information on career opportunities with Shire, please visit: www.TimeToBeBrave.com .
Shire. To be as brave as the people we help.
367 articles with Shire Pharmaceuticals
CELLECTIS SA Announces An Agreement With Shire Pharmaceuticals In The Field Of Gene Activated Proteins
FDA Committee Backs Noven Pharmaceuticals Inc.'s And Shire Pharmaceuticals' Skin Patch For Hyperactivity In Children
FDA Staffer Now Says Noven Pharmaceuticals Inc. And Shire Pharmaceuticals ADHD Patch Approvable; Reversing Earlier Opinion; Noven Trading Halted Ahead Of FDA Meeting On Patch
US FDA Staff Says Noven Pharmaceuticals Inc. And Shire Pharmaceuticals ADHD Patch Cannot Be Sold Safely
Shire Pharmaceuticals's New Higher Dose Formulation Of FOSRENOL(R) Approved To Reduce Serum Phosphorus In End-Stage Renal Disease Patients
Shire Pharmaceuticals Release: Extended-Release Carbamazepine Capsules Effective In Treating Acute Manic And Mixed Episodes Of Bipolar I Disorder
Nostrum Pharmaceuticals Confident Regarding Outcome Of Shire Laboratories' Carbamazepine ER Litigation
Transkaryotic Therapies, Inc. Confirms That Board of Directors Unanimously Recommends That Stockholders Approve Shire Pharmaceuticals Group plc Transaction
Transkaryotic Therapies, Inc. Reports Positive Top-Line Results Of Hunter Syndrome Pivotal Trial; Drug Data Dispel Acquisition Doubts For UK's Shire Pharmaceuticals
Shire Laboratories And Shire Pharmaceuticals Announce Collaboration On Phase III ADHD Drug Candidate; Shire To Pay Up To $500 Millon In Drug Deal
Shire Pharmaceuticals Group PLC Release: FDA Approves FOSRENOL(R) To Reduce Phosphorus Levels In End-Stage Renal Disease Patients